# ITR-251 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct07870096/  
OnCo record `nct07870096` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of ITR-251 run by ITERIA BIOPHARMA, S.L., not yet recruiting.

## Summary

ITR-251 in Patients With Advanced Solid Tumors is a phase 1 interventional study registered as NCT07870096 by ITERIA BIOPHARMA, S.L., with 46 participants planned, started 2026-10. Conditions recorded: Solid Tumor Cancer and Castration Resistant Metastatic Prostate Cancer. Interventions recorded: ITR-251, ITR-251 at RP2D, ARPI therapy and Androgen Deprivation Therapy (ADT).

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07870096
- Phase: 1
- Setting: Phase I/Ib Trial of Single Agent ITR-251 in Patients With Advanced Solid Tumors With an Expansion-Phase in Metastatic Castration-Resistant Prostate Cancer
- Sponsor: ITERIA BIOPHARMA, S.L.
- Enrolled: 46

## Sources

- ClinicalTrials.gov NCT07870096: https://clinicaltrials.gov/study/NCT07870096

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/)
- drugs: [ITR-251](https://onco.cc/drugs/itr-251/)
- companies: [Iteria Biopharma](https://onco.cc/companies/iteria-biopharma/)

---
JSON: https://onco.cc/api/v1/entities/nct07870096.json